PMID- 29584866
OWN - NLM
STAT- MEDLINE
DCOM- 20200407
LR  - 20200408
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 21
IP  - 8
DP  - 2018 Aug 1
TI  - Levels of Serum Brain-Derived Neurotropic Factor in Individuals at Ultra-High 
      Risk for Psychosis-Findings from the Longitudinal Youth at Risk Study (LYRIKS).
PG  - 734-739
LID - 10.1093/ijnp/pyy036 [doi]
AB  - BACKGROUND: Identifying biomarkers to enrich prognostication and risk predictions 
      in individuals at high risk of developing psychosis will enable stratified early 
      intervention efforts. Brain-derived neurotrophic factor has been widely studied 
      in schizophrenia and in first-episode psychosis with promising results. The aim 
      of this study was to examine the levels of serum brain-derived neurotrophic 
      factor between healthy controls and individuals with ultra-high risk of 
      psychosis. METHODS: A sample of 106 healthy controls and 105 ultra-high risk of 
      psychosis individuals from the Longitudinal Youth at Risk Study was included in 
      this study. Ultra-high risk of psychosis status was determined using the 
      Comprehensive Assessment of At-Risk Mental State at recruitment. Calgary 
      Depression Scale for Schizophrenia was used to assess the severity of depression. 
      All participants were followed up for 2 years, and ultra-high risk of psychosis 
      remitters were defined by ultra-high risk of psychosis individuals who no longer 
      fulfilled Comprehensive Assessment of At-Risk Mental State criteria at the end of 
      the study period. Levels of brain-derived neurotrophic factor were measured in 
      the serum by enzyme-linked immunosorbent assay method. RESULTS: The ultra-high 
      risk of psychosis group had significantly higher baseline levels of serum 
      brain-derived neurotrophic factor compared with the control group (3.7 vs 3.3 
      ng/mL, P=.018). However, baseline levels of serum brain-derived neurotrophic 
      factor did not predict the development of psychosis (OR=0.64, CI=0.40-1.02) or 
      remission (OR=0.83, CI=0.60-1.15) from ultra-high risk of psychosis status. 
      CONCLUSION: Findings from our study did not support a role for serum 
      brain-derived neurotrophic factor in predicting outcomes in ultra-high risk of 
      psychosis individuals. However, the finding of higher levels of serum 
      brain-derived neurotrophic factor in ultra-high risk of psychosis individuals 
      deserves further study.
CI  - (c) The Author(s) 2018. Published by Oxford University Press on behalf of CINP.
FAU - Yee, Jie Yin
AU  - Yee JY
AD  - Research Division, Institute of Mental Health, Singapore.
FAU - Lee, Tih-Shih
AU  - Lee TS
AD  - Neuroscience & Behavioural Disorders, Duke-NUS Medical School, Singapore.
FAU - Lee, Jimmy
AU  - Lee J
AD  - Research Division, Institute of Mental Health, Singapore.
AD  - North Region & Department of Psychosis, Institute of Mental Health, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Prognosis
MH  - Prospective Studies
MH  - Psychotic Disorders/*blood/diagnosis/*etiology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Young Adult
PMC - PMC6070044
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - peripheral markers
OT  - ultra-high risk of psychosis
EDAT- 2018/03/28 06:00
MHDA- 2020/04/09 06:00
PMCR- 2018/03/23
CRDT- 2018/03/28 06:00
PHST- 2017/11/22 00:00 [received]
PHST- 2018/03/23 00:00 [accepted]
PHST- 2018/03/11 00:00 [revised]
PHST- 2018/03/28 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2018/03/28 06:00 [entrez]
PHST- 2018/03/23 00:00 [pmc-release]
AID - 4953164 [pii]
AID - pyy036 [pii]
AID - 10.1093/ijnp/pyy036 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2018 Aug 1;21(8):734-739. doi: 10.1093/ijnp/pyy036.